Novartis (NVS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Novartis Revenue Highlights

Latest Revenue (Y)

$46.66B

Latest Revenue (Q)

$11.83B

Main Segment (Y)

Top 20 products

Main Geography (Y)

Americas

Novartis Revenue by Period

Novartis Revenue by Year

Date	Revenue	Change
2023-12-31	$46.66B	-9.97%
2022-12-31	$51.83B	-1.98%
2021-12-31	$52.88B	5.97%
2020-12-31	$49.90B	2.51%
2019-12-31	$48.68B	-8.44%
2018-12-31	$53.17B	6.05%
2017-12-31	$50.13B	1.41%
2016-12-31	$49.44B	-1.89%
2015-12-31	$50.39B	-6.05%
2014-12-31	$53.63B	-8.83%
2013-12-31	$58.83B	2.21%
2012-12-31	$57.56B	-3.06%
2011-12-31	$59.38B	15.15%
2010-12-31	$51.56B	14.32%
2009-12-31	$45.10B	5.92%
2008-12-31	$42.58B	9.34%
2007-12-31	$38.95B	5.98%
2006-12-31	$36.75B	12.98%
2005-12-31	$32.53B	15.15%
2004-12-31	$28.25B	13.61%
2003-12-31	$24.86B	7.40%
2002-12-31	$23.15B	19.74%
2001-12-31	$19.34B	-11.44%
2000-12-31	$21.83B	6.93%
1999-12-31	$20.42B	-11.38%
1998-12-31	$23.04B	-

Novartis generated $46.66B in revenue during NA 2023, up -9.97% compared to the previous quarter, and up 87.76% compared to the same period a year ago.

Novartis Revenue by Quarter

Date	Revenue	Change
2024-03-31	$11.83B	0.45%
2023-12-31	$11.78B	-2.61%
2023-09-30	$12.09B	-13.23%
2023-06-30	$13.94B	5.51%
2023-03-31	$13.21B	0.92%
2022-12-31	$13.09B	1.91%
2022-09-30	$12.84B	-1.86%
2022-06-30	$13.09B	2.11%
2022-03-31	$12.81B	-5.24%
2021-12-31	$13.52B	1.16%
2021-09-30	$13.37B	0.55%
2021-06-30	$13.29B	4.73%
2021-03-31	$12.69B	-2.58%
2020-12-31	$13.03B	3.92%
2020-09-30	$12.54B	7.88%
2020-06-30	$11.62B	-8.55%
2020-03-31	$12.71B	-0.06%
2019-12-31	$12.72B	1.87%
2019-09-30	$12.48B	3.81%
2019-06-30	$12.02B	4.97%
2019-03-31	$11.46B	-16.17%
2018-12-31	$13.66B	20.01%
2018-09-30	$11.39B	-15.36%
2018-06-30	$13.45B	4.05%
2018-03-31	$12.93B	-1.79%
2017-12-31	$13.16B	3.72%
2017-09-30	$12.69B	1.58%
2017-06-30	$12.49B	6.02%
2017-03-31	$11.79B	-6.51%
2016-12-31	$12.61B	2.15%
2016-09-30	$12.34B	-2.67%
2016-06-30	$12.68B	7.36%
2016-03-31	$11.81B	-7.76%
2015-12-31	$12.80B	2.56%
2015-09-30	$12.48B	-3.19%
2015-06-30	$12.90B	5.69%
2015-03-31	$12.20B	-8.63%
2014-12-31	$13.35B	0.41%
2014-09-30	$13.30B	-4.65%
2014-06-30	$13.95B	-2.04%
2014-03-31	$14.24B	-7.32%
2013-12-31	$15.36B	5.53%
2013-09-30	$14.56B	-0.99%
2013-06-30	$14.70B	3.51%
2013-03-31	$14.21B	-5.72%
2012-12-31	$15.07B	7.33%
2012-09-30	$14.04B	-3.45%
2012-06-30	$14.54B	4.51%
2012-03-31	$13.91B	-7.22%
2011-12-31	$15.00B	-0.25%
2011-09-30	$15.03B	-0.59%
2011-06-30	$15.12B	6.34%
2011-03-31	$14.22B	-1.67%
2010-12-31	$14.46B	12.82%
2010-09-30	$12.82B	7.54%
2010-06-30	$11.92B	-3.52%
2010-03-31	$12.36B	-6.00%
2009-12-31	$13.14B	16.43%
2009-09-30	$11.29B	5.10%
2009-06-30	$10.74B	8.22%
2009-03-31	$9.93B	-4.08%
2008-12-31	$10.35B	-6.18%
2008-09-30	$11.03B	2.83%
2008-06-30	$10.73B	4.99%
2008-03-31	$10.22B	0.44%
2007-12-31	$10.17B	-

Novartis generated $11.83B in revenue during Q1 2024, up 0.45% compared to the previous quarter, and up 90.39% compared to the same period a year ago.

Novartis Revenue Breakdown

Novartis Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total anti-infectives net sales	$1.20B	$1.10B	-	-	-
Top 20 products	$32.14B	$32.66B	$29.92B	$28.65B	$26.95B
Anti Infectives sold under Sandoz name	$777.00M	$707.00M	$694.00M	$784.00M	-
Rest of portfolio	$9.16B	$9.33B	$9.10B	$9.07B	$7.95B
COPD	-	-	-	$427.00M	-

Novartis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Top 20 products (74.27%), Rest of portfolio (21.17%), Total anti-infectives net sales (2.77%), and Anti Infectives sold under Sandoz name (1.80%).

Quarterly Revenue by Product

Product/Service	Jun 23	Jun 22	Jun 21	Jun 20	Jun 19
Rest of portfolio	$2.45B	$2.20B	$2.33B	$2.08B	$2.12B
Top 20 products	$8.79B	$8.26B	$8.23B	$7.10B	$7.21B
Anti Infectives sold under Sandoz name	-	$183.00M	$161.00M	$134.00M	-
Total anti-infectives net sales	-	$276.00M	$257.00M	-	-

Novartis's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Top 20 products (78.18%), and Rest of portfolio (21.82%).

Novartis Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Other countries	$20.05B	$20.81B	$19.04B	$21.10B	$22.17B
Country of domicile	$970.00M	$873.00M	$800.00M	$848.00M	$852.00M
CHINA	$3.13B	$3.05B	$2.57B	-	-
JAPAN	$2.21B	$2.68B	$2.80B	$2.66B	$3.17B
GERMANY	$4.28B	$4.87B	$4.52B	$4.12B	$4.18B
FRANCE	$2.26B	$2.52B	$2.44B	$2.44B	$2.71B
Americas	$21.54B	$20.46B	$19.73B	-	-
Europe	-	-	-	$5.12B	-
US	-	-	-	$2.49B	-
UNITED STATES	-	-	-	$16.28B	$17.56B
Asia/Africa/Australasia	-	-	-	$1.34B	-
Canada and Latin America	-	-	-	$784.00M	-

Novartis's latest annual revenue breakdown by geography, as of Dec 22: Americas (39.57%), Other countries (36.85%), GERMANY (7.86%), CHINA (5.75%), FRANCE (4.15%), JAPAN (4.05%), and Country of domicile (1.78%).

Quarterly Revenue by Country

Country	Jun 19
Asia/Africa/Australasia	$333.00M

Novartis's latest quarterly revenue breakdown by geography, as of Jun 19: Asia/Africa/Australasia (100.00%).

Novartis Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JNJ	Johnson & Johnson	$85.15B	$22.47B
MRK	Merck	$60.12B	$16.66B
PFE	Pfizer	$58.50B	$17.70B
ABBV	AbbVie	$54.32B	$14.46B
NVS	Novartis	$46.66B	$11.83B
AZN	AstraZeneca	$45.81B	$12.68B
BMY	Bristol-Myers Squibb Company	$45.01B	$11.89B
SNY	Sanofi	$43.07B	$11.12B
LLY	Eli Lilly and Company	$34.12B	$11.44B
GSK	GSK	$30.33B	$7.36B
GILD	Gilead Sciences	$27.12B	$7.55B

NVS Revenue FAQ

What is Novartis’s yearly revenue?

Novartis's yearly revenue for 2023 was $46.66B, representing a decrease of -9.97% compared to 2022. The company's yearly revenue for 2022 was $51.83B, representing a decrease of -1.98% compared to 2021. NVS's yearly revenue for 2021 was $52.88B, representing an increase of 5.97% compared to 2020.

What is Novartis’s quarterly revenue?

Novartis's quarterly revenue for Q1 2024 was $11.83B, a 0.45% increase from the previous quarter (Q4 2023), and a -10.44% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $11.78B, a -2.61% decrease from the previous quarter (Q3 2023), and a -10.02% decrease year-over-year (Q4 2022). NVS's quarterly revenue for Q3 2023 was $12.09B, a -13.23% decrease from the previous quarter (Q2 2023), and a -5.84% decrease year-over-year (Q3 2022).

What is Novartis’s revenue growth rate?

Novartis's revenue growth rate for the last 3 years (2021-2023) was -11.76%, and for the last 5 years (2019-2023) was -4.14%.

What are Novartis’s revenue streams?

Novartis's revenue streams in c 22 are Total anti-infectives net sales, Top 20 products, Anti Infectives sold under Sandoz name, and Rest of portfolio. Total anti-infectives net sales generated $1.2B in revenue, accounting 2.77% of the company's total revenue, up 9.09% year-over-year. Top 20 products generated $32.14B in revenue, accounting 74.27% of the company's total revenue, down -1.61% year-over-year. Anti Infectives sold under Sandoz name generated $777M in revenue, accounting 1.80% of the company's total revenue, up 9.90% year-over-year. Rest of portfolio generated $9.16B in revenue, accounting 21.17% of the company's total revenue, down -1.84% year-over-year.

What is Novartis’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Novartis was Top 20 products. This segment made a revenue of $32.14B, representing 74.27% of the company's total revenue.